Business Context and Reporting Period
This Form 8-K was filed by NanoVibronix, Inc. (not Envue Medical, Inc.) on January 7, 2025. The filing reports a material corporate event involving the unregistered sale of equity securities pursuant to Item 3.02.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific securities exchange transaction.
Material Changes and Transaction Details
On January 7, 2025, the Company entered into a Securities Exchange Agreement with an institutional investor. The Company issued new securities in exchange for the cancellation of an outstanding Series A-1 warrant held by the investor.
- Securities Issued:
- 456,478 shares of Common Stock.
- One Warrant to purchase up to 1,744,186 shares of Common Stock.
- One Pre-Funded Warrant to purchase up to 1,959,447 shares of Common Stock.
- Securities Cancelled:
- Series A-1 Warrant to purchase up to 2,906,977 shares at an exercise price of $1.47 per share.
- New Warrant Terms:
- Exercise Price: $0.62088 per share.
- Term: 5.5 years from the date of stockholder approval.
- Condition: Issuance of Warrant Shares is subject to stockholder approval under Nasdaq Capital Market rules.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, or commentary on future financial performance. The transaction was executed in reliance on an exemption from registration under Section 3(a)(9) of the Securities Act of 1933. The securities issued are not registered and may not be offered or sold in the United States absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the total number of shares issued immediately (456,478) versus the potential dilution from the Warrant (1,744,186) and Pre-Funded Warrant (1,959,447).
- Confirm the status of the required stockholder approval for the Warrant Shares, as their issuance is contingent upon this approval.
- Review the reduction in the exercise price from the cancelled warrant ($1.47) to the new warrant ($0.62088) and its impact on shareholder dilution.
- Check subsequent filings for the outcome of the stockholder vote regarding the Warrant Shares.